Tesamorelin

Tesamorelin (trans-3-hexenoyl-GHRH(1-44), also known as TH9507) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone with a single chemical modification: a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification shields the Tyr1-Ala2 peptide bond — the primary cleavage site for dipeptidyl peptidase-4 (DPP-4) — from enzymatic degradation, extending the plasma half-life from approximately 7 minutes (native GHRH) to 26–38 minutes while fully preserving GHRH receptor specificity and downstream signaling.

The mechanism is physiological rather than pharmacological: tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs → Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → GH gene transcription and pulsatile GH secretion. Because GHRHR activation amplifies the pituitary's endogenous GH pulse-generating machinery rather than forcing a fixed GH output, tesamorelin preserves the natural pulsatile pattern of GH secretion — unlike exogenous recombinant human GH, which produces a single supraphysiological peak followed by prolonged suppression of endogenous secretion. The downstream IGF-1 elevation is similarly physiological, tracking the endogenous regulatory set-point rather than exceeding it.

This preserved feedback integrity is the fundamental advantage of GHRH-analog therapy over exogenous GH: the hypothalamic-pituitary-somatostatin-IGF-1 feedback loop remains intact, preventing the supraphysiological IGF-1 elevations and unopposed GH effects that complicate rhGH administration. The clinical endpoint — selective reduction of visceral adipose tissue — is driven by the lipolytic effects of enhanced GH pulsatility on visceral adipocytes, which express higher GH receptor density and are more hormonally responsive than subcutaneous adipose tissue.

Tesamorelin was developed by Theratechnologies (Montreal) in the early 2000s, emerging from research into GHRH analogs as potential treatments for HIV-associated lipodystrophy — a disfiguring and metabolically harmful accumulation of visceral fat that affected a large proportion of patients on first-generation antiretroviral therapy. Two pivotal Phase 3 trials demonstrated that tesamorelin 2mg daily reduced visceral adipose tissue by approximately 15–18% over 26 weeks versus placebo, with effects reversing upon discontinuation — confirming the treatment was suppressive rather than curative of the underlying adipose dysregulation.

The FDA approved tesamorelin as Egrifta in November 2010, making it the first and only FDA-approved medication specifically indicated for reduction of excess abdominal fat in HIV-associated lipodystrophy. This was a landmark regulatory decision: it validated a body-composition endpoint as clinically meaningful and established the GH axis as a legitimate target for adipose-tissue pharmacology. Research interest has since expanded to tesamorelin's effects on liver fat (NAFLD), cognitive function (through IGF-1-mediated neurotrophic effects), and healthy-aging body-composition maintenance — all areas where preserved physiological feedback regulation offers theoretical advantages over recombinant GH.

Store lyophilized tesamorelin at -20°C in a light-protected, desiccated container. As a full-length 44-amino-acid peptide, tesamorelin is structurally more complex than short GHRPs (6 AA) and correspondingly more sensitive to degradation. The trans-3-hexenoyl N-terminal modification provides DPP-4 resistance but does not protect against all degradation pathways — careful adherence to storage conditions is warranted. Stability exceeds 18 months at -20°C.

After reconstitution, the pharmaceutical formulation (Egrifta) specifies immediate use or storage at 2–8°C for up to 24 hours. Independent research protocols using bacteriostatic water typically extend this to 7–14 days at 2–8°C, though degradation accelerates noticeably after day 7 — the long peptide chain is more susceptible to aqueous hydrolysis than short GHRPs. Reconstituted tesamorelin should be protected from light and not agitated vigorously. Do not freeze reconstituted solutions, as ice-crystal formation can shear the long peptide chain.